Newer treatments for type 2 diabetes have been shown to slow down the progression of chronic kidney disease only in patients with high protein levels in their urine, according to a study out this week.<\/p>\n
The authors of the US study said their findings support taking albuminuria measurements into account when deciding on type 2 diabetes treatments for people at risk of developing chronic kidney disease.<\/p>\n
\u201cGLP-1 receptor agonists or SGLT-2 inhibitors slowed the decrease in renal function in people with type 2 diabetes with moderately increased albuminuria\u201d<\/p>\n
Study authors<\/p>\n
Previous studies have suggested that patients with type 2 diabetes<\/a> who take a glucagon-like peptide-1 (GLP-1) receptor agonist or sodium glucose cotransporter 2 (SGLT-2) inhibitor may have a slower progression of chronic kidney disease than people given other treatments.<\/p>\n The current study, published in the British Medical Journal<\/a>, looked to see if this renal<\/a> impact was as strong in people without protein in their urine as it was in those with protein in their urine \u2013 albuminuria.<\/p>\n The study included data from more than 75,000 patients with type 2 diabetes who were taking either a GLP-1 receptor agonist, an SGLT-2 inhibitor, a sulfonylurea or a dipeptidyl peptidase-4 (DPP-4) inhibitor.<\/p>\n At the start of the study, all the participants had moderate cardiovascular risk and kidney function that ranged from normal to mildly impaired. Just over 18% of the participants also had albuminuria.<\/p>\n After an average follow-up of 32 months, the researchers saw a protective effect from GLP-1 agonist or SGLT-2 inhibitor treatment on kidney function only in people with albuminuria.<\/p>\n Compared to people given DPP-4 treatment, those with albuminuria given a GLP-1 or SGLT-2 drug were 40% less likely to experience a significant loss of kidney function over five years, the researchers found.<\/p>\n But in the majority who did not have albuminuria, the risk of a significant decline in kidney function over five years was similar in those taking a GLP-1 or SGLP-2 inhibitor and those taking a DPP-4 inhibitor.<\/p>\n However, those without albuminuria who received sulfonylurea treatment were 31% more likely to experience significant loss of kidney function over five years compared to those taking DPP-4 inhibitors.<\/p>\n The researchers said their results underscored the importance of taking into account albuminuria when making treatment decisions for diabetes patients who were at risk of developing chronic kidney disease.<\/p>\n They said: \u201cCompared with DPP-4 inhibitors, GLP-1 receptor agonists or SGLT-2 inhibitors slowed the decrease in renal function in people with type 2 diabetes with moderately increased albuminuria, but not in those without albuminuria.\u201d<\/p>\n They added: \u201cSulfonylureas led to faster decline in renal function in people with type 2 diabetes and normo-albuminuria.<\/p>\n \u201cThese results underscore the importance of considering albuminuria when making treatment decisions for people with type 2 diabetes at risk of declining renal function,\u201d the researchers said.<\/p>\n \u201cPrevention of deterioration of kidney function in people without albuminuria remains a challenge,\u201d noted the study authors from Brigham and Women\u2019s Hospital in Boston.<\/p>\n They added that further research was needed to identify treatments that could prevent the progression of kidney disease in the large population of people with type 2 diabetes without albuminuria.<\/p>\n GLP-1 drugs research timeline<\/p>\n","protected":false},"excerpt":{"rendered":"Newer treatments for type 2 diabetes have been shown to slow down the progression of chronic kidney disease…\n","protected":false},"author":2,"featured_media":627333,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[103,61,60,371],"class_list":["post-627332","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-ie","tag-ireland","tag-medication"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/627332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=627332"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/627332\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/627333"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=627332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=627332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=627332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}